f the U.S. wants to effectively combat high drug costs and make medicines affordable, the federal government needs to take several aggressive, if controversial steps, according to a sweeping and ambitious report from the National Academies of Sciences, Engineering, and Medicine.

The recommendations include a bevy of familiar notions:

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to cari larsen Cancel reply

Please enter your name.
Please enter a comment.

  • No matter how long and how many days the drug pricing is discussed there are two conflicting facts that prevent lower drug prices. One is profits and the other is pharma companies capitalizing on human desire/weakness to extend life at all costs. Another fact no one wants to discuss is lobbying effort where politicians are bought and sold to assure drug prices stay high.

    Pharma uses inefficient processes to produce drugs and their is no effort to improve processes as the regulators interfere. They have a task to assure quality is maintained but companies at times cut corners. Companies won’t agree with what I am saying but in the name of profits shortcuts are way of life in manufacturing.

    Only way prices can be lowered is price control.

  • Won’t denying tax deductions for direct-to-consumer drug advertising actually cause drug manufacturers to pass on more marketing costs to consumers in the form of higher drug prices? I wish there was more talk about banning direct-to-consumer prescription drug advertising entirely, the costs of which already contribute to higher drug prices. The United States and New Zealand are the only industrialized nations in which such advertising is not banned.

    • Hi Elizabeth,
      Thanks for your note. The report is very lengthy, but if you dig in, there is mention of encouraging industry to end direct to consumer advertising. There would like be a free speech fight if Washington were to attempt to regulate this, but the issue was noted.
      ed at pharmalot

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.